IL6 and retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache syndrome: This clinical case description adds to the growing body of evidence supporting the role of targeted therapies in managing ROSAH syndrome, offers insights into the broader implications of IL-6 blockade in autoinflammatory diseases, and helps expanding ROSAH phenotype.